Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s Macroglobulinemia
December 15th 2020Christian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.